Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 94.4% in April

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 24,100 shares, an increase of 94.4% from the March 31st total of 12,400 shares. Based on an average daily volume of 49,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Trading of Theratechnologies

Several hedge funds have recently modified their holdings of THTX. AIGH Capital Management LLC increased its stake in shares of Theratechnologies by 362.9% in the 4th quarter. AIGH Capital Management LLC now owns 3,719,302 shares of the company’s stock valued at $6,025,000 after acquiring an additional 2,915,906 shares in the last quarter. Worth Venture Partners LLC increased its stake in shares of Theratechnologies by 362.5% in the 4th quarter. Worth Venture Partners LLC now owns 906,557 shares of the company’s stock valued at $1,469,000 after acquiring an additional 710,551 shares in the last quarter. Wealthspire Advisors LLC bought a new stake in shares of Theratechnologies in the 4th quarter valued at $83,000. National Bank of Canada FI increased its stake in shares of Theratechnologies by 65.4% in the 4th quarter. National Bank of Canada FI now owns 113,378 shares of the company’s stock valued at $191,000 after acquiring an additional 44,825 shares in the last quarter. Finally, Summit Trail Advisors LLC bought a new stake in shares of Theratechnologies in the 1st quarter valued at $55,000.

Theratechnologies Price Performance

Theratechnologies stock remained flat at $1.30 during mid-day trading on Friday. 12,985 shares of the company’s stock traded hands, compared to its average volume of 20,393. Theratechnologies has a 52-week low of $0.88 and a 52-week high of $4.30. The firm’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.53. The firm has a market capitalization of $31.46 million, a PE ratio of -2.13 and a beta of 1.34.

Theratechnologies (NASDAQ:THTX) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.16. The firm had revenue of $23.45 million for the quarter. During the same period last year, the firm posted ($0.36) EPS. On average, analysts forecast that Theratechnologies will post -0.03 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Theratechnologies in a report on Friday, January 12th.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.